Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Net Income

Bottom-line profit after all expenses, interest, and taxes.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$7.03M, compared with -$7.26M a year earlier. Trailing-twelve-month net income was -$29.44M.

Context

  • Net income amounted to 1817.1% of revenue in FY2025, down 1103.0 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 3 analysts of -$10.78M (+63.7%) for the fiscal year ending Dec 2026, a step up from the +1.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.03M+31.8% QoQ
Last fiscal yearDec 2025
-$29.67M+1.1% YoY
LTMMar 2026
-$29.44M+1.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.2%-39.8%-43.0 pp
1 year+1.1%+63.7%+62.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(29.67M) USD
Year-over-year change
+1.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1.2% is the 3rd highest of 9, against a peer median of -14.6%.
  • Net income amounts to 929.1% of revenue for RANI, versus a peer median of 1764.5%.
RANI Competitors
Net Income for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$29.44M USD+1.2%—929.1%
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$40.19M USD+21.6%——
CRDFCardiff Oncology, Inc.LTM Mar 2026-$44.76M USD+8.4%—8526.1%
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$68.36M USD-31.7%—3832.0%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.06M CHF-17.4%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.53M USD-68.1%——
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$123.33M USD-55.2%—356.9%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026-$147.39M USD-11.7%—839.5%
Peer median (excluding RANI) —-14.6%—1764.5%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.